FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

被引：0
|
作者：
Li, Qiao
Cheng, Ying
Tong, Zhongsheng
Liu, Yunjiang
Wang, Xian
Yan, Min
Chang, Jianhua
Wang, Shusen
Du, Caiwen
Li, Liang
Wu, Chunjiao
Wang, Mingxia
Wang, Zhuo
Wu, Zhuli
Jin, Yongli
Zhang, Yongjiao
Hui, Ai-Min
Wang, Xingli
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Hebei Med Univ, Dept Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[6] Zhengzhou Univ, Dept Breast Dis, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Chinese Acad Med Sci, Shenzhen Ctr, Dept Med Oncol, Canc Hosp, Shenzhen, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[10] Meizhou Peoples Hosp, Dept Med Oncol, Meizhou, Guangdong, Peoples R China
[11] Jilin Canc Hosp, Dept Oncol, Phase ward 1, Changchun, Jilin, Peoples R China
[12] Hebei Med Univ, Dept Phase 1, Clin Trial Unit, Hosp 4, Shijiahuang, Hebei, Peoples R China
[13] Beijing Fosun Pharmaceut Res & Dev Co Ltd, Shanghai, Peoples R China
[14] Fosun Pharma USA Inc, Lexington, MA USA
[15] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3044
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
    Shitara, Kohei
    Yamaguchi, Kensei
    Muro, Kei
    Yasui, Hisateru
    Sakai, Daisuke
    Oshima, Takashi
    Fujimura, Masahiro
    Sato, Yuta
    Yamazaki, Shunsuke
    Wakabayashi, Tatsuya
    Sugihara, Masahiro
    Kamio, Takahiro
    Shoji, Hirokazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (01) : 27 - 35
  • [42] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
    Kohei Shitara
    Kensei Yamaguchi
    Kei Muro
    Hisateru Yasui
    Daisuke Sakai
    Takashi Oshima
    Masahiro Fujimura
    Yuta Sato
    Shunsuke Yamazaki
    Tatsuya Wakabayashi
    Masahiro Sugihara
    Takahiro Kamio
    Hirokazu Shoji
    International Journal of Clinical Oncology, 2024, 29 : 27 - 35
  • [43] Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial.
    Li, Huan
    Li, Zhaohui
    Yan, Min
    Cui, Xiujie
    Ji, Xuening
    Fang, Fenqi
    Zhang, Yuyang
    Wang, Xiaoxin
    Wang, Yan
    Guo, Xiangyu
    Jing, Mingxi
    Gao, Zhichao
    Cao, Hui
    Dong, Fangyuan
    Wu, Jie
    Jiang, Cui
    Duan, Yangyang
    Li, Xiaorui
    Jiang, Yujun
    Sun, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Gianni, Luca
    Pienkowski, Tadeusz
    Im, Young-Hyuck
    Roman, Laslo
    Tseng, Ling-Ming
    Liu, Mei-Ching
    Lluch, Ana
    Staroslawska, Elzbieta
    de la Haba-Rodriguez, Juan
    Im, Seock-Ah
    Pedrini, Jose Luiz
    Poirier, Brigitte
    Morandi, Paolo
    Semiglazov, Vladimir
    Srimuninnimit, Vichien
    Bianchi, Giulia
    Szado, Tania
    Ratnayake, Jayantha
    Ross, Graham
    Valagussa, Pinuccia
    LANCET ONCOLOGY, 2012, 13 (01): : 25 - 32
  • [45] Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.
    Chen, Zhanhong
    Wang, Xiaojia
    Huang, Jian
    Zheng, Yabing
    Shao, Xiying
    Cao, Wenming
    Chen, Junqing
    Ye, Weiwu
    Ping, Huang
    Li, Guangliang
    Lei, Lei
    Shi, Lei
    Huang, Yuan
    Zou, Weibin
    Wang, Rong
    Shen, Xia-Bo
    Lou, Caijin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [47] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [48] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [49] Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry
    Ibragimova, Khava I. E.
    Geurts, Sandra M. E.
    Laczko, David
    Meegdes, Marissa
    Erdkamp, Frans
    Heijns, Joan B.
    Tol, Jolien
    Vriens, Birgit E. P. J.
    Aaldering, Kirsten N. A.
    Dercksen, Marcus W.
    Pepels, Manon J. A. E.
    Peters, Natascha A. J. B.
    van de Winkel, Linda M. H.
    van de Wouw, Agnes J.
    de Fallois, Aude
    van Kats, Maartje A. C. E.
    Tjan-Heijnen, Vivianne C. G.
    CLINICAL BREAST CANCER, 2024, 24 (02) : 103 - 111
  • [50] Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    Javle, Milind
    Borad, Mitesh J.
    Azad, Nilofer S.
    Kurzrock, Razelle
    Abou-Alfa, Ghassan K.
    George, Ben
    Hainsworth, John
    Meric-Bernstam, Funda
    Swanton, Charles
    Sweeney, Christopher J.
    Friedman, Claire F.
    Bose, Ron
    Spigel, David R.
    Wang, Yong
    Levy, Jonathan
    Schulze, Katja
    Cuchelkar, Vaikunth
    Patel, Arisha
    Burris, Howard
    LANCET ONCOLOGY, 2021, 22 (09): : 1290 - 1300
12345